Background: Aluminium-containing phosphate binders have long been used for treatment of hyperphosphatemia in dialysis patients. Their safety became controversial in the early 1980's after reports ...

The treatment of hyperphosphatemia was intensified by the additional mealtime administration of phosphate binders, such as aluminium hydroxide and calcium carbonate. Phosphate accumulation was ...

Hyperphosphatemia is linked to increased mortality risk. Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate ...

A change in Medicare coverage for some dialysis medications has left nursing homes and their patients receiving in-house treatment for kidney failure in a serious bind.

The review highlights the challenges faced by patients regarding current phosphate binders, particularly focusing on issues like high pill burdens and gastrointestinal side effects, which ...

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new ...

Dialysis patients often face a high daily pill burden, with phosphate binders making up about 50% of the total. Nonadherence to phosphate binders is a significant challenge contributing to ...

(MENAFN- GlobeNewsWire - Nasdaq) Large pill size, high pill burden and palatability were identified as key barriers for phosphate binder adherence LOS ALTOS, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE ...